Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Naming Rights: Biosimilar Influence Efforts Continue Before Products Take The Field

Executive Summary

FDA isn’t immune to political pressure, but a group of senators arguing that biosimilars should be given the same International Nonproprietary Name as their branded counterparts will need to make a stronger case than citing the agency’s own previous analysis.


Related Content

Biosimilars: FDA, EMA Developing Common Data Package Guidance
Track-And-Trace Insufficient For Biosimilar Pharmacovigilance, Brand Companies Say
Is FDA Reviewing A Biosimilar Marketing Application?
Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Biosimilar Suffix Naming Idea Trips On Dispensing Problem
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Botox Safety Emphasized By FDA As Botulinum Toxins Get New Generic Names


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts